Search research articles
Contact Us
Filters
Showing results (121-130 of 183) with videos related to
Page
of 19
Sort By:
Plos One
|
November 25, 2020
Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancer
Jan A Stratmann, Raphael Lacko, Olivier Ballo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 28, 2010
Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer
Joan H Schiller, Joachim von Pawel, Philipp Schütt, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society
|
January 20, 2022
Role of renin-angiotensin system antagonists on long-term mortality post-percutaneous coronary intervention in reduced and preserved ejection fraction
Hamish C Prosser, Kah Yong Peck, Diem Dinh, et al.
The American Journal of Cardiology
|
August 7, 2021
Totally Occluded Culprit Coronary Artery in Patients with Non-ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Himawan Fernando, Stephen J Duffy, Ashlea Low, et al.
Oncology Research and Treatment
|
June 20, 2017
Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536
Frank Breitenbuecher, Joachim von Pawel, Martin Sebastian, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
December 15, 2021
Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung)
Martin Sebastian, Andreas Gröschel, Sylvia Gütz, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 20, 2017
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer
Thomas Wehler, Michael Thomas, Christian Schumann, et al.
Journal of Cancer Research and Clinical Oncology
|
May 17, 2023
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting
Oliver Kraskowski, Jan A Stratmann, Marcel Wiesweg, et al.
Clinical Transplantation
|
June 23, 2026
Conversion to LCP Tacrolimus Mitigates Calcineurin-Induced Nephrotoxicity in Patients After Liver Transplantation
Maximilian Joseph Brol, Isabella Munske, Iyad Kabar, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions
|
November 12, 2024
Understanding long-term risk in Percutaneous Coronary Intervention (PCI) in the Australian contemporary era with a focus on defining Complex Revascularisation in High-Risk Indicated Patients (CHIP)
Julian Yeoh, Garry W Hamilton, Diem Dinh, et al.
Page
of 19
Search research articles
Search
Showing results (121-130 of 183) with videos related to
Sort By:
Page
of 19
Plos One
|
November 25, 2020
Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancer
Jan A Stratmann, Raphael Lacko, Olivier Ballo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 28, 2010
Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer
Joan H Schiller, Joachim von Pawel, Philipp Schütt, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society
|
January 20, 2022
Role of renin-angiotensin system antagonists on long-term mortality post-percutaneous coronary intervention in reduced and preserved ejection fraction
Hamish C Prosser, Kah Yong Peck, Diem Dinh, et al.
The American Journal of Cardiology
|
August 7, 2021
Totally Occluded Culprit Coronary Artery in Patients with Non-ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Himawan Fernando, Stephen J Duffy, Ashlea Low, et al.
Oncology Research and Treatment
|
June 20, 2017
Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536
Frank Breitenbuecher, Joachim von Pawel, Martin Sebastian, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
December 15, 2021
Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung)
Martin Sebastian, Andreas Gröschel, Sylvia Gütz, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 20, 2017
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer
Thomas Wehler, Michael Thomas, Christian Schumann, et al.
Journal of Cancer Research and Clinical Oncology
|
May 17, 2023
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting
Oliver Kraskowski, Jan A Stratmann, Marcel Wiesweg, et al.
Clinical Transplantation
|
June 23, 2026
Conversion to LCP Tacrolimus Mitigates Calcineurin-Induced Nephrotoxicity in Patients After Liver Transplantation
Maximilian Joseph Brol, Isabella Munske, Iyad Kabar, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions
|
November 12, 2024
Understanding long-term risk in Percutaneous Coronary Intervention (PCI) in the Australian contemporary era with a focus on defining Complex Revascularisation in High-Risk Indicated Patients (CHIP)
Julian Yeoh, Garry W Hamilton, Diem Dinh, et al.
Page
of 19